Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds like fake news. LOL But i'm riding the $ODYY train!!!!
LOL
$ODYY up 44% today with no end in sight!!!!!
Congrats Fun. Being up 45% today alone is just the beginning. Go $ODYY!!!!!
$ODYY up 20% so far today!!!!
$ODYY accumulation continues!!![
$ODYY continues to improve!!!
Thanks Cap!!
$TQLB NEWS OUT!!!
Torque Issues Letter to Shareholders on Launch of Multiple High Growth Brand Opportunities in $20B Sports Nutrition and Supplements Market
Press Release | 02/04/2021
WHEAT RIDGE, CO February 4, 2021 Torque Lifestyle Brands Inc. (OTCMKTS:TQLB) (Torque Lifestyle or the Company), an emerging leader in the active lifestyle sports nutrition and supplements marketplace, issues the following letter to shareholders on behalf of its CEO:
Dear Valued Shareholder,
First off, thank you for your support, loyalty, commitment, and patience. Torque is set to move forward with a bold new vision as we near commercial launch of multiple brands in the sports nutrition and supplements market. We have laid down a promising foundation, and I wanted to take the time today to highlight what we have set in motion and where we believe it will lead.
We are moving fast and expect a number of important developments in coming weeks. At this point, we are imminently launching two brands and working actively toward completing an acquisition that promises to jumpstart our overall positioning by complementing our knowledge and product capital with existing brand value and a broad distribution footprint.
We will have further details on the acquisition over coming days.
Outside of that acquisition, we are launching two brands that target complementary and broadly non-overlapping markets within the broader sports nutrition and supplements marketplace.
The first of these is Core Natural Supplements a health and nutrition brand targeting health-conscious consumers in the 35 and up demographic. Core focuses on supplements including Turmeric and will interface with the market primarily through ecommerce and affiliate marketing strategies. Core has already launched.
The second brand set to launch is Storm Lifestyle, which targets a younger demographic through apparel, supplements, beverages, and gear designed to appeal to a hardcore active lifestyle. Storm will go to market through a combination of direct-to-consumer and physical store distribution strategies. Storm is set to launch this month.
We will release additional details about these brands over the near term as we ramp up commercial launch activity and explore synergy opportunities following upcoming strategic steps.
In addition, over coming days we will release further details about our primary acquisition candidate. For now, I can tell you that, provided next steps play out as we anticipate, this deal promises to add another, already revenue generating, and complementary piece to the puzzle, driving additional non-overlapping market penetration in the same broad category of sports nutrition and supplements, while also providing a network of relationships poised to significantly expand our physical store distribution footprint, which will substantially augment our ability to drive sales to our Storm Lifestyle branded products as well.
Our broad target marketplace is a rapidly growing space. Analysts currently put the sports nutrition market at anywhere from $15-20 billion in annual global sales, growing at around 10%. Within that wide market definition, we see several faster growing niches, which is where we are focusing our investments.
As noted at the outset, things are moving quickly at this point now that we have a distinct vision and are actively engaged in the commercial launch of multiple brands with a key acquisition in the works that stands to position us as a significant force in the ketogenic products (Keto) marketplace as well. We look forward to providing additional updates over coming days and weeks as we make further progress.
Best Regards,
David Lovatt
Chief Executive Officer
About Torque Lifestyle Brands Inc.
Torque Lifestyle Brands Inc. (OTCMKTS:TQLB) is focused on driving performance through acquisitions and by advancing original brands in the rapidly growing supplemental nutrition marketplace.
Cautionary Statement Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Companys expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding departure of the companys CEO. When used herein, the words anticipate, believe, estimate, upcoming, plan, target, intend and expect and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Companys actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Corporate Contact:
invest@torquelb.com
Investor Relations Contact:
EDM Media, LLC
https://edm.media
(800) 301-7883
$TQLB NEWS OUT!!!
Torque Issues Letter to Shareholders on Launch of Multiple High Growth Brand Opportunities in $20B Sports Nutrition and Supplements Market
Press Release | 02/04/2021
WHEAT RIDGE, CO February 4, 2021 Torque Lifestyle Brands Inc. (OTCMKTS:TQLB) (Torque Lifestyle or the Company), an emerging leader in the active lifestyle sports nutrition and supplements marketplace, issues the following letter to shareholders on behalf of its CEO:
Dear Valued Shareholder,
First off, thank you for your support, loyalty, commitment, and patience. Torque is set to move forward with a bold new vision as we near commercial launch of multiple brands in the sports nutrition and supplements market. We have laid down a promising foundation, and I wanted to take the time today to highlight what we have set in motion and where we believe it will lead.
We are moving fast and expect a number of important developments in coming weeks. At this point, we are imminently launching two brands and working actively toward completing an acquisition that promises to jumpstart our overall positioning by complementing our knowledge and product capital with existing brand value and a broad distribution footprint.
We will have further details on the acquisition over coming days.
Outside of that acquisition, we are launching two brands that target complementary and broadly non-overlapping markets within the broader sports nutrition and supplements marketplace.
The first of these is Core Natural Supplements a health and nutrition brand targeting health-conscious consumers in the 35 and up demographic. Core focuses on supplements including Turmeric and will interface with the market primarily through ecommerce and affiliate marketing strategies. Core has already launched.
The second brand set to launch is Storm Lifestyle, which targets a younger demographic through apparel, supplements, beverages, and gear designed to appeal to a hardcore active lifestyle. Storm will go to market through a combination of direct-to-consumer and physical store distribution strategies. Storm is set to launch this month.
We will release additional details about these brands over the near term as we ramp up commercial launch activity and explore synergy opportunities following upcoming strategic steps.
In addition, over coming days we will release further details about our primary acquisition candidate. For now, I can tell you that, provided next steps play out as we anticipate, this deal promises to add another, already revenue generating, and complementary piece to the puzzle, driving additional non-overlapping market penetration in the same broad category of sports nutrition and supplements, while also providing a network of relationships poised to significantly expand our physical store distribution footprint, which will substantially augment our ability to drive sales to our Storm Lifestyle branded products as well.
Our broad target marketplace is a rapidly growing space. Analysts currently put the sports nutrition market at anywhere from $15-20 billion in annual global sales, growing at around 10%. Within that wide market definition, we see several faster growing niches, which is where we are focusing our investments.
As noted at the outset, things are moving quickly at this point now that we have a distinct vision and are actively engaged in the commercial launch of multiple brands with a key acquisition in the works that stands to position us as a significant force in the ketogenic products (Keto) marketplace as well. We look forward to providing additional updates over coming days and weeks as we make further progress.
Best Regards,
David Lovatt
Chief Executive Officer
About Torque Lifestyle Brands Inc.
Torque Lifestyle Brands Inc. (OTCMKTS:TQLB) is focused on driving performance through acquisitions and by advancing original brands in the rapidly growing supplemental nutrition marketplace.
Cautionary Statement Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Companys expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding departure of the companys CEO. When used herein, the words anticipate, believe, estimate, upcoming, plan, target, intend and expect and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Companys actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Corporate Contact:
invest@torquelb.com
Investor Relations Contact:
EDM Media, LLC
https://edm.media
(800) 301-7883
$ODYY volume accumulation. Hmmmmmmmmm
Yup. Threw up a bid and never saw it. GLTY
$ODYY NEWS OUT!!!! AMAZING VIDEO!!
Odyssey Group International's Planned Acquisition of Concussion Drug from Prevacus, Inc. Enhances Delivery Capabilities with Nasal Therapeutic
Press Release | 01/26/2021
Provides Safer and Faster Access to the Brain
IRVINE, CA / ACCESSWIRE / January 26, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce it is circulating a video to better define its drug candidate PRV-002, a therapeutic compound drug to treat concussion (mild traumatic brain injury (mTBI), from Prevacus Inc.
For an overview demonstration of the nasal therapeutic delivery, please view:
$ODYY NEWS OUT!!! AMAZING VIDEO!!!
Odyssey Group International's Planned Acquisition of Concussion Drug from Prevacus, Inc. Enhances Delivery Capabilities with Nasal Therapeutic
Press Release | 01/26/2021
Provides Safer and Faster Access to the Brain
IRVINE, CA / ACCESSWIRE / January 26, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce it is circulating a video to better define its drug candidate PRV-002, a therapeutic compound drug to treat concussion (mild traumatic brain injury (mTBI), from Prevacus Inc.
For an overview demonstration of the nasal therapeutic delivery, please view:
Welcome Bud. Preliminary results are very favorable. Because of all the notoriety of concussions, i'm thinking this in line for the FDA fast-track program. JMHO and GLTY $ODYY
$ODYY ACCUMULATION CONTINUES!!!!
Bids moving up!! We see $20.00 plus on FDA approval $ODYY!! JMHO
$ODYY will soar above $20.00 on FDA approval. Keep on watchlist!!!
$ODYY gaining momentum!!!
$DGDM volume increase today!!!
$DGDM volume picking up!!!
Brett Favre $ODYY tweets continue!! Something brewing??
$ODYY Bids moving up on positive news!!!
Absolutely!! $ODYY could be a game changer in the fight against concussions... JMHO
$ODYY NEWS OUT!!
Odyssey Group International's Planned Acquisition of Concussion Drug from Prevacus, Inc. Provides Positive Data from Ongoing Stability Studies
Press Release | 01/20/2021
Stability Temperatures Ideal for Transportation and Storage, Suitable for Sports Playing Fields and Military Operations
IRVINE, CA / ACCESSWIRE / January 20, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that its planned acquisition of drug candidate PRV-002, a concussion drug therapeutic compound (mild traumatic brain injury (mTBI)), from Prevacus, Inc. ("Prevacus") www.prevacus.com has received updated data from ongoing stability studies.
A study by a third party shows the drug is stable at 104º F for up to 6 months and stable at 77º F for up to 12 months. The drug stability means that the drug can be transported and stored in most environments around the globe. The current stability shows the drug is stable particularly for sports playing fields and for military operations. The stability is important in that allows for easy shipment and storage of the drug, unlike some drugs such as a Covid-19 vaccine, the concussion drug will not have unique or difficult storage requirements.
The Company plans further stability studies up to 125º F.
Several notable professional athletes have endorsed Prevacus and its drug development effort, including Brett Favre, who has long been an investor in Prevacus and endorsed the science in hopes of bringing a therapeutic treatment for concussion to market. See the Prevacus website "news" section for other notable pro-athletes who have endorsed this effort; https://prevacus.com/news/.
Odyssey previously entered into a definitive agreement to acquire the Active Pharmaceutical Ingredient PRV-002 to treat traumatic brain injury on January 11, 2021. The definitive agreement has been signed and the transaction is expected to close by the end of February 2021 with the transaction conditional on Prevacus shareholder approval and other customary closing conditions.
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
P: 619-832-2900
info@odysseygi.com
ClearThink
nyc@clearthink.capital
SOURCE: Odyssey Group International, Inc.
$ODYY NEWS OUT!!
Odyssey Group International's Planned Acquisition of Concussion Drug from Prevacus, Inc. Provides Positive Data from Ongoing Stability Studies
Press Release | 01/20/2021
Stability Temperatures Ideal for Transportation and Storage, Suitable for Sports Playing Fields and Military Operations
IRVINE, CA / ACCESSWIRE / January 20, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that its planned acquisition of drug candidate PRV-002, a concussion drug therapeutic compound (mild traumatic brain injury (mTBI)), from Prevacus, Inc. ("Prevacus") www.prevacus.com has received updated data from ongoing stability studies.
A study by a third party shows the drug is stable at 104º F for up to 6 months and stable at 77º F for up to 12 months. The drug stability means that the drug can be transported and stored in most environments around the globe. The current stability shows the drug is stable particularly for sports playing fields and for military operations. The stability is important in that allows for easy shipment and storage of the drug, unlike some drugs such as a Covid-19 vaccine, the concussion drug will not have unique or difficult storage requirements.
The Company plans further stability studies up to 125º F.
Several notable professional athletes have endorsed Prevacus and its drug development effort, including Brett Favre, who has long been an investor in Prevacus and endorsed the science in hopes of bringing a therapeutic treatment for concussion to market. See the Prevacus website "news" section for other notable pro-athletes who have endorsed this effort; https://prevacus.com/news/.
Odyssey previously entered into a definitive agreement to acquire the Active Pharmaceutical Ingredient PRV-002 to treat traumatic brain injury on January 11, 2021. The definitive agreement has been signed and the transaction is expected to close by the end of February 2021 with the transaction conditional on Prevacus shareholder approval and other customary closing conditions.
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
P: 619-832-2900
info@odysseygi.com
ClearThink
nyc@clearthink.capital
SOURCE: Odyssey Group International, Inc.
$ODYY NEWS OUT!!
dyssey Group International's Planned Acquisition of Concussion Drug from Prevacus, Inc. Provides Positive Data from Ongoing Stability Studies
Press Release | 01/20/2021
Stability Temperatures Ideal for Transportation and Storage, Suitable for Sports Playing Fields and Military Operations
IRVINE, CA / ACCESSWIRE / January 20, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that its planned acquisition of drug candidate PRV-002, a concussion drug therapeutic compound (mild traumatic brain injury (mTBI)), from Prevacus, Inc. ("Prevacus") www.prevacus.com has received updated data from ongoing stability studies.
A study by a third party shows the drug is stable at 104º F for up to 6 months and stable at 77º F for up to 12 months. The drug stability means that the drug can be transported and stored in most environments around the globe. The current stability shows the drug is stable particularly for sports playing fields and for military operations. The stability is important in that allows for easy shipment and storage of the drug, unlike some drugs such as a Covid-19 vaccine, the concussion drug will not have unique or difficult storage requirements.
The Company plans further stability studies up to 125º F.
Several notable professional athletes have endorsed Prevacus and its drug development effort, including Brett Favre, who has long been an investor in Prevacus and endorsed the science in hopes of bringing a therapeutic treatment for concussion to market. See the Prevacus website "news" section for other notable pro-athletes who have endorsed this effort; https://prevacus.com/news/.
Odyssey previously entered into a definitive agreement to acquire the Active Pharmaceutical Ingredient PRV-002 to treat traumatic brain injury on January 11, 2021. The definitive agreement has been signed and the transaction is expected to close by the end of February 2021 with the transaction conditional on Prevacus shareholder approval and other customary closing conditions.
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
P: 619-832-2900
info@odysseygi.com
ClearThink
nyc@clearthink.capital
SOURCE: Odyssey Group International, Inc.
View source version on accesswire.com:
https://www.accesswire.com/625001/Odyssey-Group-Internationals-Planned-Acquisition-of-Concussion-Drug-from-Prevacus-Inc-Provides-Positive-Data-from-Ongoing-Stability-Studies
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
OTCQB Member Since 11/2019
OTCQB
OTCQB Venture
Verified Profile 10/2020
$ODYY Endorsements keep coming!!!
Steve Mariucci
@SteveMariucci
·
38m
https://google.com/amp/s/sports.yahoo.com/amphtml/odyssey-group-international-acquire-concussion-130000224.html…. Congrats to Prevacus and Odyssey $ODYY getting a deal done to push a treatment forward for our athletes who sustain concussions !
Odyssey Group International to Acquire Concussion Drug Asset from Prevacus, Inc.
All Stock Transaction Phase 1 Clinical Trial Site, Protocol and CRO EstablishedIRVINE, CA / ACCESSWIRE / January 11, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey...
sports.yahoo.com
3
3
Steve Mariucci Retweeted
NFL Media
@NFLMedia
·
22h
MASSIVE editions of
@NFLGameDay
Morning this weekend
@nflnetwork
*Saturday Noon ET
@SteveMariucci
w/ Sean McVay
@michaelirvin88
w/ Davante Adams & Cole Beasley
@joethomas73
@Hawk
@MoveTheSticks
join
*Sunday 11a ET
@WillieMcGinest
w/ Rob Gronkowski
@heykayadams
w/ Sean Payton
2
5
19
Show this thread
Steve Mariucci Retweeted
Frank Caliendo
@FrankCaliendo
·
Jan 12
Here you go
@RobGronkowski
History narrated by Morgan Freeman... sort of.
316
5.8K
21.5K
Show this thread
Steve Mariucci Retweeted
NFL GameDay
@NFLGameDay
·
Jan 10
"Alvin Kamara, you are unbelievable!!!"
Mooch's Minute today is dedicated to the greatness of
@A_kamara6
??
@Saints
@SteveMariucci
2
6
36
Steve Mariucci Retweeted
Stephen Ray
@StephenRayMusic
·
Jan 6
I had the pleasure of writing this song with my friend
@bearredell
. Give Church and Cash by Bear Redell a listen on Apple or Spotify and let us know what you think. #countrymusic #ericchurch #johnnycash
3
8
New to Twitter?
Sign up now to get your own personalized timeline!
Sign up
Image
Image
Image
Image
Image
Image
You might like
trey wingo
@wingoz
Follow
Jason La Canfora
@JasonLaCanfora
Follow
Coach Steve Mariucci on board $ODYY!!!
Steve Mariucci
@SteveMariucci
·
38m
https://google.com/amp/s/sports.yahoo.com/amphtml/odyssey-group-international-acquire-concussion-130000224.html…. Congrats to Prevacus and Odyssey $ODYY getting a deal done to push a treatment forward for our athletes who sustain concussions !
Odyssey Group International to Acquire Concussion Drug Asset from Prevacus, Inc.
All Stock Transaction Phase 1 Clinical Trial Site, Protocol and CRO EstablishedIRVINE, CA / ACCESSWIRE / January 11, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey...
sports.yahoo.com
3
3
Steve Mariucci Retweeted
NFL Media
@NFLMedia
·
22h
MASSIVE editions of
@NFLGameDay
Morning this weekend
@nflnetwork
*Saturday Noon ET
@SteveMariucci
w/ Sean McVay
@michaelirvin88
w/ Davante Adams & Cole Beasley
@joethomas73
@Hawk
@MoveTheSticks
join
*Sunday 11a ET
@WillieMcGinest
w/ Rob Gronkowski
@heykayadams
w/ Sean Payton
2
5
19
Show this thread
Steve Mariucci Retweeted
Frank Caliendo
@FrankCaliendo
·
Jan 12
Here you go
@RobGronkowski
History narrated by Morgan Freeman... sort of.
316
5.8K
21.5K
Show this thread
Steve Mariucci Retweeted
NFL GameDay
@NFLGameDay
·
Jan 10
"Alvin Kamara, you are unbelievable!!!"
Mooch's Minute today is dedicated to the greatness of
@A_kamara6
??
@Saints
@SteveMariucci
2
6
36
Steve Mariucci Retweeted
Stephen Ray
@StephenRayMusic
·
Jan 6
I had the pleasure of writing this song with my friend
@bearredell
. Give Church and Cash by Bear Redell a listen on Apple or Spotify and let us know what you think. #countrymusic #ericchurch #johnnycash
3
8
New to Twitter?
Sign up now to get your own personalized timeline!
Sign up
Image
Image
Image
Image
Image
Image
You might like
trey wingo
@wingoz
Follow
Jason La Canfora
@JasonLaCanfora
Follow
$ODYY gaining some attention!!
$ODYY grabbing some attention!!
Abby Wambach also on board $ODYY!!!
Abby Wambach
@AbbyWambach
·
1h
Congrats to Prevacus and Odyssey for getting a deal done to push a treatment forward for any athletes who sustain concussions! One giant step closer:)LFG!! $ODYY
Odyssey Group International to Acquire Concussion Drug Asset from Prevacus, Inc.
All Stock Transaction Phase 1 Clinical Trial Site, Protocol and CRO EstablishedIRVINE, CA / ACCESSWIRE / January 11, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey...
finance.yahoo.com
7
37
Abby Wambach
@AbbyWambach
·
Jan 8
Seth, this thread is amazing!! I’ve held the Espy for almost a decade. It’s nice. And I’ll do this:
@MoneyLynch
if you want. Tradesies, this Espy for your NFL pension. ??????
Quote Tweet
Seth Meyers
@sethmeyers
· Jan 8
Watching this play sent me down a memory hole that gave me goosebumps as well as a pang of guilt. Let me explain. A THREAD! twitter.com/FieldYates/sta…
Show this thread
6
14
419
Abby Wambach
@AbbyWambach
·
Jan 6
Me!!!! ????????????????????????????
Quote Tweet
LeBron James
@KingJames
· Jan 6
Think I’m gone put together an ownership group for the The Dream. Whose in? #BlackVotesMatter???
Image
29
104
2.8K
Abby Wambach
@AbbyWambach
·
Jan 5
I BELIEVE.
Let’s Go, GA!!
Quote Tweet
Stacey Abrams
@staceyabrams
· Jan 5
Our time is now, Georgia. Vote today: http://iwillvote.com #gapol #gasen
5
42
639
Abby Wambach Retweeted
Stacey Abrams
@staceyabrams
·
Jan 5
MSNBC is reporting that voters at many Atlanta Metro polling places are in and out in 5 minutes today because so many Georgians voted early! So if you haven't voted, get out and vote by 7PM today. I'm counting on you. #gapol #gasen
2.2K
47.4K
242.8K
Abby Wambach
@AbbyWambach
·
Jan 2
This is what leadership looks like. my wife just said to me: “every answer he gives reveals who he really is on the inside. He is beautiful.” Sending you love and admiration Coach.
Quote Tweet
Dan Woike
@DanWoikeSports
· Jan 1
Gregg Popovich's full answer on why he didn't think Becky Hammon coaching was a 'big deal.' "We didn't hire Becky to make history. She earned it."
Show this thread
Image
29
395
5.4K
New to Twitter?
Sign up now to get your own personalized timeline!
Sign up
Image
Image
Image
Image
Image
Image
You might like
Carli Lloyd
@CarliLloyd
Follow
$ODYY Abby Wambach Tweets on board!!!!
Abby Wambach
@AbbyWambach
·
1h
Congrats to Prevacus and Odyssey for getting a deal done to push a treatment forward for any athletes who sustain concussions! One giant step closer:)LFG!! $ODYY
Odyssey Group International to Acquire Concussion Drug Asset from Prevacus, Inc.
All Stock Transaction Phase 1 Clinical Trial Site, Protocol and CRO EstablishedIRVINE, CA / ACCESSWIRE / January 11, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey...
finance.yahoo.com
7
37
Abby Wambach
@AbbyWambach
·
Jan 8
Seth, this thread is amazing!! I’ve held the Espy for almost a decade. It’s nice. And I’ll do this:
@MoneyLynch
if you want. Tradesies, this Espy for your NFL pension. ??????
Quote Tweet
Seth Meyers
@sethmeyers
· Jan 8
Watching this play sent me down a memory hole that gave me goosebumps as well as a pang of guilt. Let me explain. A THREAD! twitter.com/FieldYates/sta…
Show this thread
6
14
419
Abby Wambach
@AbbyWambach
·
Jan 6
Me!!!! ????????????????????????????
Quote Tweet
LeBron James
@KingJames
· Jan 6
Think I’m gone put together an ownership group for the The Dream. Whose in? #BlackVotesMatter???
Image
29
104
2.8K
Abby Wambach
@AbbyWambach
·
Jan 5
I BELIEVE.
Let’s Go, GA!!
Quote Tweet
Stacey Abrams
@staceyabrams
· Jan 5
Our time is now, Georgia. Vote today: http://iwillvote.com #gapol #gasen
5
42
639
Abby Wambach Retweeted
Stacey Abrams
@staceyabrams
·
Jan 5
MSNBC is reporting that voters at many Atlanta Metro polling places are in and out in 5 minutes today because so many Georgians voted early! So if you haven't voted, get out and vote by 7PM today. I'm counting on you. #gapol #gasen
2.2K
47.4K
242.8K
Abby Wambach
@AbbyWambach
·
Jan 2
This is what leadership looks like. my wife just said to me: “every answer he gives reveals who he really is on the inside. He is beautiful.” Sending you love and admiration Coach.
Quote Tweet
Dan Woike
@DanWoikeSports
· Jan 1
Gregg Popovich's full answer on why he didn't think Becky Hammon coaching was a 'big deal.' "We didn't hire Becky to make history. She earned it."
Show this thread
Image
29
395
5.4K
New to Twitter?
Sign up now to get your own personalized timeline!
Sign up
Image
Image
Image
Image
Image
Image
You might like
Carli Lloyd
@CarliLloyd
Follow
David Ross ex cubby tweets out $ODYY!!!!!
David Ross
@D_Ross3
·
2h
https://google.com/amp/s/sports.yahoo.com/amphtml/odyssey-group-international-acquire-concussion-130000224.html… Congrats to prevacus and odyssey getting a deal done to push a treatment forward for our kid athletes who sustain concussions
Odyssey Group International to Acquire Concussion Drug Asset from Prevacus, Inc.
All Stock Transaction Phase 1 Clinical Trial Site, Protocol and CRO EstablishedIRVINE, CA / ACCESSWIRE / January 11, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey...
sports.yahoo.com
4
29
David Ross
@D_Ross3
·
Jan 5
??
Quote Tweet
DOM
@DOM_Frederic
· Jan 4
boog is going to be absolutely fantastic in chicago
20
104
1.6K
David Ross
@D_Ross3
·
Jan 5
We got a good one folks!!
Quote Tweet
Marquee Sports Network
@WatchMarquee
· Jan 5
Waking up this morning like
Image
Image
41
107
3.1K
David Ross
@D_Ross3
·
Dec 4, 2020
Gonna miss this guy!
Quote Tweet
Chicago Cubs
@Cubs
· Dec 4, 2020
16 incredible seasons and countless “Oh baby!” calls, you brought so many iconic Cubs moments to life.
Thank you, @LenKasper.
61
119
3.2K
David Ross
@D_Ross3
·
Nov 23, 2020
??
Quote Tweet
Auburn Baseball
@AuburnBaseball
· Nov 23, 2020
How 'bout this nugget from @jaysonst on @AUTimHudson's case for the Hall of Fame? ??
#WarEagle
Image
3
11
169
New to Twitter?
Sign up now to get your own personalized timeline!
Sign up
Image
Image
Image
Image
Image
Image
You might like
Anthony Rizzo
@ARizzo44
Follow
Kris Bryant
@KrisBryant_23
Follow
$DGDM volume increase today!! Could be EPA approval...
Brett Favre just tweeted about $ODYY. What's the connection here?
Brett Favre just tweeted on $ODYY, That's huge!!
Brett Favre
@BrettFavre
·
8m
Congrats to
@PrevacusInc
and Odyssey (ODYY) on the Concussion deal! ??
Brett Favre just tweeted on $ODYY. HUGE
Brett Favre
@BrettFavre
·
8m
Congrats to
@PrevacusInc
and Odyssey (ODYY) on the Concussion deal! ??
Brett Favre just tweeted on $ODYY!!! HUGE
Brett Favre
@BrettFavre
·
8m
Congrats to
@PrevacusInc
and Odyssey (ODYY) on the Concussion deal! ??
$ODYY HUGE NEWS Brett Favre involved!!
Odyssey Group International to Acquire Concussion Drug Asset from Prevacus, Inc.
Press Release | 01/11/2021
All Stock Transaction
Phase 1 Clinical Trial Site, Protocol and CRO Established
IRVINE, CA / ACCESSWIRE / January 11, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce it has entered into a definitive agreement to acquire drug candidate PRV-002, a concussion drug therapeutic compound (mild traumatic brain injury (mTBI)), from Prevacus, Inc. (“Prevacus”) www.prevacus.com.
The definitive agreement has been signed and the transaction is expected to close by the end of February 2021, the transaction is conditional on Prevacus shareholder approval and other customary closing conditions.
There are more than 3 million sports and recreational concussions in the U.S. each year with an additional estimated 1.5 million that go unreported. These figures do not include a high number of concussions sustained in other high-risk incidents including motor vehicle accidents and elderly falls. Given the high incidence rate of concussion and its impact on patient care, the market for a treatment is estimated to be over $2 billion dollars annually.
Several notable professional athletes have endorsed Prevacus and its drug development effort, including Brett Favre, who has long been an investor in Prevacus and endorsed the science in hopes of bringing a therapeutic treatment for concussion to market. See the Prevacus website "news" section for other notable pro-athletes who have endorsed this effort; https://prevacus.com/news/.
Dr. Jake Vanlandingham, Prevacus Chief Executive Officer, will join Odyssey and continue to be instrumental in the development of PRV-002 focused on a treatment for concussion (mild traumatic brain injury (mTBI)). Dr. Vanlandingham, stated, "We are very excited to join forces with Odyssey in further development of the first drug to treat concussion. The Odyssey management group and funding mechanism will immediately allow us to continue the development of our unique nanoparticle drug in the nasal device by dramatically enhancing PRV-002 delivery to the brain," said Dr. Vanlandingham. "The concussion drug has been proven to be safe and effective in animal models and preparations are underway for a Phase 1 human clinical trial this year."
Odyssey Chairman and Chief Executive Officer Michael Redmond, commented, "We have been in a joint partnership with Prevacus for the past couple of years, and have been able to witness the early development and progress of PRV-002 and its potential for treatment of concussion. We are now thrilled to own the asset, have Dr. Vanlandingham join us in bringing it to a Phase 1 human clinical trial and have Odyssey shareholders directly benefit in the potential value created by PRV-002. We look forward to closing the all-stock acquisition by the end of February."
Concussion has become an epidemic in sports, military and elderly populations. The heterogenous nature of a traumatic brain injury requires a treatment that can work on many molecular fronts. PRV-002, through gene amplification has shown to reduce swelling, inflammation and oxidative stress simultaneously. Animal toxicology data shows a significant safety margin. Animal brain biodistribution studies show drug availability in less than 5-minutes.
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
p619-832-2900
info@odysseygi.com
ClearThink